About Switch Therapeutics
Switch Therapeutics is a preclinical-stage biotechnology company pioneering RNA interference (RNAi) therapies using its proprietary CASi (Conditionally Activated siRNA) platform, which combines single- and double-stranded RNA properties in a single molecule to enable cell-selective gene knockdown. The company focuses on central nervous system (CNS) diseases and other indications with significant unmet need, developing biomarker-gated genetic medicines that activate only in targeted cell populations. Its technology is based on discoveries from researchers at Caltech, Harvard Medical School, and City of Hope.
Company details
Funding
Total raised
$52M
Last stage
Series A
Investors
Founders
Dee Datta
PhD from Caltech, MBA from Stanford GSB. Previously Chief Business Officer at XOMA and VP Corporate Development at Forty Seven, Inc. Earlier career as VC at The Column Group and Longitude Capital.
LinkedInSi-Ping Han
Co-inventor of the CASi platform. Led the invention and early development of Switch's core technology before transitioning to the Scientific Advisory Board in 2024.
Saumya Das
Associate Professor at Harvard Medical School with an MD and PhD in Neurobiology and Neuroscience. His lab focuses on biomarkers for disease phenotypes and extracellular RNA research.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.